Tirupati Starch’s growth post the recent capex and the jump in cash from operations looks mixed: strong on scale and cash generation in FY25, but still fragile on margins, leverage and consistency in FY26.

---

1. What the recent capex has done

- The company has undertaken a sizeable capex over FY23–FY25 to:

- Add liquid glucose as a new product.

- Increase existing starch capacity, which temporarily kept utilisation subdued during FY24. (acuite.in)

- As a result, gross block and net PPE have almost trebled from FY23 to FY25 (net PPE ~₹55 Cr → ~₹119 Cr → ~₹139 Cr), confirming a large expansion phase. (livemint.com)

This is a clear move from a smaller, relatively de‑levered starch player to a larger, more asset‑heavy and debt‑funded platform.

---

2. Growth so far post-capex (up to FY25 & 9M FY26)

Revenue and profit:

- FY23 revenue: ₹364.7 Cr; PAT: ₹6.6 Cr (PAT margin ~1.8%). (acuite.in)

- FY24 revenue: fell to ~₹306.3 Cr (‑16% YoY) as the company executed capex and capacity utilisation stayed low, but OPM improved to 6.76% (from 5.89%). PAT dropped to ₹2.1 Cr. (acuite.in)

- FY25 revenue: rebounded strongly to about ₹390 Cr (c. +27% YoY over FY24) as the expanded capacity ramped up. However, rating commentary notes weaker profitability in 9M FY26, linked to debt‑funded capex and lower margins. (groww.in)

Quarterly trend (FY25–FY26):

- From Mar’25 to Mar’26, quarterly revenue is in a narrow band of ~₹90–100 Cr, showing that the new capacity is being used, but:

- Net margins are thin, mostly ~1.5–2.7%, and

- One quarter (Sep’25 / Q2 FY26) saw profit almost vanish (~₹0.01 Cr) despite ~₹90 Cr revenue. (groww.in)

Debt and leverage:

- Total debt rose sharply with the capex: ₹89.9 Cr (FY23) → ₹153.5 Cr (FY24), then eased to ₹135.9 Cr (FY25) as repayments started.

- Equity increased from ~₹46 Cr (FY23) to ~₹61 Cr (FY25), but debt‑to‑equity is still high (~2.2x). Rating agencies highlight this leverage and working‑capital intensity as constraints. (livemint.com)

Cash from operations and FCF:

- Operating cash flow (OCF) turned sharply higher in FY25:

- FY23 OCF: ~₹23 Cr

- FY24 OCF: negative ~₹34 Cr (heavy working-capital build + capex period)

- FY25 OCF: ~₹49 Cr, helped by much better EBITDA and a large positive working‑capital swing. (stockanalysis.com)

- Capex in each of FY23–FY25 has been in the ₹26–31 Cr range, but in FY25 the strong OCF allowed:

- Positive free cash flow (~₹22 Cr) and

- Some deleveraging (debt reduced ~₹18 Cr vs FY24). (stockanalysis.com)

So, “high cash from operations this year” is real, but it is partly driven by one‑time working‑capital release on top of better operating performance; it may not be structurally repeatable at the same magnitude every year.

---

3. How growth looks post-capex from here

From a fundamental standpoint (not a recommendation), the post‑capex picture looks like this:

Positives for growth:

1. Higher scale base:

- With FY25 revenue ~₹390 Cr, the company has scaled meaningfully from FY23 levels, and the expanded plant plus liquid glucose should be able to support mid‑teens revenue growth for a few years without another big capex, if utilisation continues to rise and demand holds. (groww.in)

2. Product mix upgrade:

- The addition of liquid glucose and value‑added starch derivatives opens up higher‑value end‑markets (confectionery, bakery, pharma, processed foods). That can support better average realisations and margins versus plain commodity starch, provided the company builds stable customers in these segments. (tirupatistarch.com)

3. Improved internal funding capacity:

- A year of strong OCF and positive FCF demonstrates that, once working capital normalises and the new plant is sweating, the business can fund maintenance capex and some debt reduction from internal cash instead of further aggressive borrowing. (stockanalysis.com)

Key constraints and risks to that growth:

1. Earnings still volatile despite higher capacity:

- The Q2 FY26 result (profit down ~99% QoQ; PAT margin ~0.01%) shows that a small change in spreads (maize prices vs finished product realisations) or utilisation can wipe out profits, even at current scale. (marketsmojo.com)

2. Leverage remains high:

- D/E above 2x and rating commentary of “stretched” liquidity mean that growth is happening from a leveraged balance sheet, with interest coverage only moderate. This amplifies both upside and downside: good years of volume/margin expansion can drive strong PAT growth, but weak quarters can quickly strain cash flows. (acuite.in)

3. Working-capital sensitivity:

- OCF in FY25 benefited heavily from a favourable working‑capital movement (~₹200 Cr swing). If inventory or receivables rise again (for example, in a downcycle or if credit terms loosen to drive volumes), operating cash can fall sharply even if reported PAT looks stable. (stockanalysis.com)

4. Commodity and competitive pressure:

- Maize prices are volatile, industry is fragmented, and pricing power is limited, as highlighted by the rating rationale. This inherently caps sustainable margin expansion unless the company can migrate a larger share of revenue to more specialised, higher‑margin derivatives. (acuite.in)

---

4. Putting it together

- Scale growth: Post‑capex, the company has clearly grown in size (revenue up from ~₹306 Cr in FY24 to ~₹390 Cr in FY25) and has the physical capacity to maintain or grow volumes further without a fresh large capex in the near term. (acuite.in)

- Profit growth: Earnings growth is not yet stable; quarterly results and rating commentary show that margins and ROE/ROCE are still volatile and sensitive to raw‑material costs, utilisation and interest burden. (groww.in)

- Cash-flow strength: FY25 shows that once capacity is sweating and working capital is managed tightly, the business can generate healthy operating cash and even positive free cash flow after capex, which is supportive for future growth and deleveraging. But investors should treat FY25’s very high OCF as partly cyclical (WC release), not purely structural. (stockanalysis.com)

In summary, post‑capex growth in Tirupati Starch looks encouraging on revenue and operating cash, but fragile on profitability and balance‑sheet quality. The next leg of growth will depend less on more capex, and more on:

- Sustained utilisation of the expanded capacity and liquid glucose line,

- Ability to defend/improve margins in a commodity‑like industry, and

- Gradual reduction of leverage to de‑risk the model.

For detailed numbers, you can cross‑check the latest Acuite rating note, the company’s annual reports on its website, and consolidated financials on platforms like Groww, Livemint and StockAnalysis.

If you have any further queries, please connect with us on 022-6290-10141 (Timings : 09.00 AM to 05.00 PM) or you can email us on info@cniinfoxchange.com